ValiRx plc (GB:VAL) has released an update.
ValiRx plc, a life science company dedicated to developing early-stage cancer treatments and women’s health solutions, announced the successful passing of all resolutions at their Annual General Meeting (AGM), except for resolution 11. The company, known for expediting the transition from innovative science to impactful medicines, has a history of out-licensing lead candidates for further development and commercialization. Detailed voting results will soon be posted on the company’s website.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
